IL-27 in tumor immunity and immunotherapy.

Abstract

Inflammation has a central role in cancer progression. Metastatic tumors arise at sites of chronic inflammation, and tumors or tumor-infiltrating immune cells produce inflammatory mediators. By contrast, natural killer (NK) cells and cytotoxic T cells (CTLs) help eliminate premalignant lesions and limit the rate of tumor metastasis. Interleukin (IL)-27 is an IL-12 family cytokine chiefly produced by antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages, and alone or in combination with other cytokines, IL-27 boosts antitumor immunity by contributing to the development of NK cells and CTLs - a central immnunomodulatory effect - and by exerting potent antiangiogenic and antimetastatic activities, a local antitumor effect. In this review, we argue that by virtue of its rate-limiting functions in innate and adaptive immune responses, modulating IL-27 holds considerable promise for future cancer immunotherapy.

• Authors: Gopal Murugaiyan, Bhaskar Saha
• Journal: Trends in molecular medicine (Trends Mol Med) Vol. 19 Issue 2 Pg. 108-16 (Feb 2013) ISSN: 1471-499X [Electronic] England
• PMID: 23306374 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2012 Elsevier Ltd. All rights reserved.

Chemical References

• Interleukin-17
• Receptors, Interleukin

Topics

• Adaptive Immunity
• Animals
• Humans
• Immunity, Innate
• Immunosuppression Therapy
• Immunotherapy
• Inflammation (immunology)
• Interleukin-17 (immunology, metabolism)
• Neoplasms (immunology, pathology, therapy)
• Neovascularization, Pathologic (immunology, metabolism)
• Receptors, Interleukin (immunology, metabolism)
• T-Lymphocytes, Regulatory (immunology)